A radioactive tumor-targeting peptide that grips its target twice stuck around in tumors longer, and shrank them better, than the version now in human trials. The redesign, reported online September 8 in Bioorganic Chemistry ↗, is a fix for the oldest problem in this class of drugs: the missile finds the tumor, then washes back out before it has delivered enough radiation.
The target is fibroblast activation protein, or FAP. It sits on the surface of cancer-associated fibroblasts, the support cells that pack the tissue around many solid tumors, so it marks the tumor's neighborhood even when the cancer cells themselves are hard to hit. Attach a targeting molecule to a radioactive metal and you get a theranostic: pair it with gallium-68 and the tumor lights up on a PET scan, swap in lutetium-177 and the same molecule ferries a dose of radiation to the spot. The idea is elegant. The engineering problem is retention.
Two grips instead of one
The benchmark FAP peptide, called FAP-2286, is already in human trials, and like most FAP radioligands it clears out of tumors quickly. Fast washout means less radiation deposited per injection, which caps how much therapy you can deliver.
The authors built six new molecules on a different principle. Each fuses a small-molecule FAP-inhibitor fragment (chemically, a 2-cyanopyrrolidine or a 2-pyrrolidinylboronic acid group) onto a cyclic peptide that also binds FAP. The result is heterobivalent: one molecule with two different hands, both reaching for the same protein. They then tuned the linkers and attachment points, labeled everything with gallium-68, and reached radiochemical purity above 95 percent with good stability in the dish.
The two-handed grip did what a firmer hold should. Against FAP, the heterobivalent molecules bound more tightly than the single-handed FAP-2286. In cultured U87MG cells they were taken up more, pulled deeper inside the cell, and leaked back out less than their one-armed counterparts.
Better retention, better kill, in mice
In mice carrying U87MG tumors, PET scans showed the tracers clearing fast from healthy tissue while piling up in the tumor. One candidate, tagged in the paper as compound 5, gave the highest tumor uptake and the cleanest tumor-to-background contrast. Switched to the therapeutic isotope lutetium-177, that same compound posted the most favorable tumor-to-kidney exposure ratio and slowed tumor growth significantly more than lutetium-177 on FAP-2286.
That tumor-to-kidney number matters more than it sounds. The kidneys are where radioactive peptides tend to concentrate and cause collateral damage, so a molecule that loads the tumor harder without loading the kidney harder is solving the real bottleneck, not just moving the dose around.
Where the caution goes
This is a mouse-and-dish study, and the tumor model is a glioma cell line rather than the stroma-rich human cancers where FAP imaging has drawn the most interest. The abstract keeps its efficacy claims qualitative, so the improvement over FAP-2286 is reported as a direction, not a percentage. Compound 5 is also the best of six the team made, which is how medicinal chemistry works but also means the headline is a survivor of its own screen. None of this has touched a patient.
The logic, though, is the same one that has already paid off elsewhere. A separate group made a somatostatin-targeting radioligand linger longer and saw a 44 percent response in a small human trial ↗. Residence time is the currency of radioligand therapy, and adding a second grip is a clean way to buy more of it. Whether the two-handed FAP molecule holds that advantage when it leaves the mouse is the question a trial will have to answer.